anti-idiotype HER2 vaccine (Institut de Recherche en Cancerologie de Montpellier/INSERM)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-idiotype HER2 vaccine (Institut de Recherche en Cancerologie de Montpellier/INSERM)

Drug Alias NameScFv 69/ScFv 40 HER2 vaccine (Institut de Recherche en Cancerologie de Montpellier)anti-idiotypic antibody 1HE

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesInstitut De Recherche En Cancérologie De Montpellier (Ircm)

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInstitut De Recherche En Cancérologie De Montpellier (Ircm)Inserm Transfert

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A